SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg4/28/2005 1:08:22 PM
  Read Replies (1) of 3044
 
Millennium Pharma's Drive For Long-Term Growth
04.28.05, 12:52 PM ET

Credit Suisse First Boston maintained a "hold" rating on Millennium Pharmaceuticals (nasdaq: MLNM - news - people ) after the biotechnology company reported results for the first quarter. Millennium reported Thursday morning a first-quarter loss of 9 cents per share, compared with CSFB's estimated loss of 17 cents per share.

The company posted a narrower-than-expected loss on higher Velcade sales milestones from partner Ortho Biotech, a unit of Johnson & Johnson (nyse: JNJ - news - people ), and lower research and development spending. "Much debate has centered on Millennium's ability to reach 2006 profitability without a reacceleration of revenue growth or drastic cost cuts. We are more concerned about long-term earnings prospects and project 2008 earnings-per-share of just 13 cents," said CSFB. "We believe Millennium will seek late-stage in-licensing opportunities over the next year in a bid to drive longer-term growth, at the potential expense of 2006 profits."

The research firm narrowed its 2005 forecasted loss of 38 cents per share from 31 cents per share and trimmed the price target on Millennium to $12 from $14. CSFB noted that the most appealing program in the company's early pipeline is MLN1202, a multiple sclerosis treatment.

forbes.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext